Symptomatic Non-erosive Gastroesophageal Reflux Disease
Oncology
Prevalence
10903.8 / 100K
Incidence
4267.4 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| dexlansoprazole | Mylan II B.V. (MYL) |
Frequently asked questions
How many drugs are in development for Symptomatic Non-erosive Gastroesophageal Reflux Disease?
BioSniper tracks 1 drug in development for Symptomatic Non-erosive Gastroesophageal Reflux Disease across 1 company.
How many clinical trials target Symptomatic Non-erosive Gastroesophageal Reflux Disease?
There are 1 clinical trial targeting Symptomatic Non-erosive Gastroesophageal Reflux Disease tracked by BioSniper.
What is the prevalence of Symptomatic Non-erosive Gastroesophageal Reflux Disease?
The estimated prevalence of Symptomatic Non-erosive Gastroesophageal Reflux Disease is approximately 10903.8 per 100,000 population.
Deep-dive into Symptomatic Non-erosive Gastroesophageal Reflux Disease
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis